Lavipharm S.A. (ATH:LAVI)

Market Cap	264.02M +97.4%
Revenue (ttm)	64.53M +23.0%
Net Income	5.18M -45.5%
EPS	0.03
Shares Out	170.78M
PE Ratio	51.78
Forward PE	n/a
Dividend	0.02 (1.28%)
Ex-Dividend Date	n/a

Volume	12,986
Open	1.550
Previous Close	1.546
Day's Range	1.550 - 1.558
52-Week Range	0.734 - 1.738
Beta	1.01
Analysts	n/a
Price Target	n/a
Earnings Date	May 28, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 285
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2025, Lavipharm's revenue was 62.58 million, an increase of 18.20% compared to the previous year's 52.95 million. Earnings were 5.99 million, a decrease of -33.36%.